In the endocrine surgical world, a new debate has emerged-that being which operation is the best for sporadic primary hyperparathyroidism (HPT). Advances in technology, preoperative imaging, and intra-operative adjuncts have expanded the operative choices for our patients [1, 2] . No longer is it a mandatory 4-gland bilateral parathyroid exploration as it was in the days of Oliver Cope [3] . Today, with appropriate patient selection, surgeons are successfully utilizing a more focused approach such as imaged-directed or unilateral explorations in order to avoid a bilateral exploration and the additional risks [4] [5] [6] . However, recent data have emerged that 10-year cure rates following a focused approach may be lower than bilateral exploration [7, 8] . It has been long recognized that if one looks at all the glands at the initial operation, more histological abnormal glands are found [9] . Siperstein et al. found unrecognized multi-gland disease 16 % of the time when they proceeded to a 4-gland exploration following a 'successful' focused parathyroidectomy [10] . That, along with the fact that the now-recognized incidence of elevated PTH with normal calcium levels following parathyroid surgery (a potential harbinger for recurrence) appears to be higher following a focused approach compared to a bilateral exploration [11] [12] [13] , has at least caused me to pause and reflect on which operation for sporadic HPT is the best. I attempted to bring about some reflection among the audience on this very topic at the 2014 Asian Association of Endocrine Surgeons meeting in Sri Lanka. I presented data demonstrating a long-term recurrence rate of 4-6 % with a focused approach compared to 1-2 % with a bilateral operation [7, 8] . Yet given over 80 % of patients with sporadic HPT have solitary adenomas, clearly the majority do achieve a life-long cure from a focused approach. I concluded my talk by stating that parathyroid surgeons need to reflect on the how far the pendulum has swung away from the gold-standard operation. A focused approach may not provide as robust long-term cure as the bilateral operation does, but it clearly has many advantages and should not be totally abandoned as some have advocated [8] . Since access to advanced preoperative imaging and adjuncts like intra-operative PTH (iPTH) are not always possible or have proven not to be cost-effective in some surgical units, many surgeons are providing an operative strategy that best suits their patients within their local healthcare environment and this is not wrong. We have to recognize that what works for one unit may not be the best strategy for another. Surgeons need to define their 'go to operation' and how successful it has been both in short-and long-term followup. When I sat down, the senior author of the Norlen paper (LD) leaned over and asked me 'why do we endocrine surgeons feel the need to give a lifetime guarantee to our operations? The orthopedic surgeons give a 5-10 year warranty on the joints they replace and that is still considered a success.'
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I have been reflecting on that provocative statement ever since. I believe our need to provide a lifetime guarantee of our work comes from our general surgical background. It is true that we guarantee no further attacks of biliary colic or appendicitis once we perform a cholecystectomy or appendectomy. Yet in our oncology work, we rarely provide a lifetime warrantee for disease-free survival at the time of informed consent. So instead of debating which parathyroid operation has superiority, we should instead be addressing which patients are at risk for persistent disease (an operative failure), which patients are at risk for longterm recurrence, and which patients would be well served with an operation that will likely last for the next 10 years. To that end, many investigators have tried to stratify patients at risk for persistent disease following a focused parathyroidectomy by utilizing peri-operative data such as the weight of the resected adenoma, the decline curve of the iPTH measurement, a rebound effect of iPTH, and/or the assessment of the ipsilateral gland [14] [15] [16] [17] .
The North Shore Unit has utilized their extensive database to retrospectively define those patients at risk for persistent disease following their operative approach to localized sporadic HPT (an image-directed parathyroidectomy without iPTH). They found that the weight of a resected gland of less than 200 mg was associated with a 6 % persistent rate compared to 2 %. For them, the overall risk of persistent disease of 3 % is acceptable and explained to the patients preoperatively. Their review identified a group of patients at risk for persistent disease (adenomas \200 mg), and as such, a more extensive follow-up program for those at-risk patients could be instituted. McCoy and the Pittsburgh unit utilized both the gland weights and the iPTH values to help decrease the risk of persistent disease by triggering a bilateral exploration at the time of the initial operation [17] . Both strategies work as long as the patient accepts the risk of a second operation versus the risk of a bilateral procedure.
The real question remains-what is the warranty on a parathyroid operation? Should it come with a lifetime guarantee? Is a 10-year warranty following a focus parathyroidectomy in an 84-year-old patient a better approach than a bilateral exploration? These are questions that the surgeon and the patient have to address. There is no single correct answer. Recognizing that a focal approach to sporadic HPT may not have the same durability as a bilateral approach, it will, however, provide normocalcemia in over 90 % of patients for up to 10 years. This should be part of the surgeons' thought processes when discussing the operative management with the patient. The ideal operation for sporadic HPT in my opinion is one that renders the patient normocalcemic for the duration of their life span with minimal operative risk. How this is achieved will depend on the health resources, local expertise, and both the patients' and surgeons' willingness to accept the persistent and recurrence rates for such an approach. Performing a bilateral exploration or utilizing peri-operative information during a focused approach both can achieve the goal of providing best operation for that patient.
